Regular
NAV (18-Jun-25)
Returns (Since Inception)
Fund Size
₹435 Cr
Expense Ratio
2.40%
ISIN
INF174KA1PW4
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+11.80%
+14.51% (Cat Avg.)
Since Inception
+19.18%
— (Cat Avg.)
Equity | ₹412.32 Cr | 94.88% |
Others | ₹22.23 Cr | 5.12% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹67.1 Cr | 15.44% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹34.32 Cr | 7.90% |
Divi's Laboratories Ltd | Equity | ₹26.45 Cr | 6.09% |
Triparty Repo | Cash - Repurchase Agreement | ₹26.1 Cr | 6.01% |
Cipla Ltd | Equity | ₹21.99 Cr | 5.06% |
Jubilant Pharmova Ltd | Equity | ₹16.43 Cr | 3.78% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹15.92 Cr | 3.66% |
Lupin Ltd | Equity | ₹14.1 Cr | 3.24% |
Apollo Hospitals Enterprise Ltd | Equity | ₹13.76 Cr | 3.17% |
Torrent Pharmaceuticals Ltd | Equity | ₹13.33 Cr | 3.07% |
Dr Reddy's Laboratories Ltd | Equity | ₹12.51 Cr | 2.88% |
Alkem Laboratories Ltd | Equity | ₹12.24 Cr | 2.82% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹12.03 Cr | 2.77% |
Aurobindo Pharma Ltd | Equity | ₹11.59 Cr | 2.67% |
Marksans Pharma Ltd | Equity | ₹11.5 Cr | 2.65% |
Zydus Lifesciences Ltd | Equity | ₹10.7 Cr | 2.46% |
Acutaas Chemicals Ltd | Equity | ₹10.59 Cr | 2.44% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹10.26 Cr | 2.36% |
Ajanta Pharma Ltd | Equity | ₹9.89 Cr | 2.28% |
Mankind Pharma Ltd | Equity | ₹9.87 Cr | 2.27% |
Sai Life Sciences Ltd | Equity | ₹9.46 Cr | 2.18% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹8.5 Cr | 1.96% |
Fortis Healthcare Ltd | Equity | ₹8.48 Cr | 1.95% |
Glenmark Pharmaceuticals Ltd | Equity | ₹8.31 Cr | 1.91% |
Innova Captab Ltd | Equity | ₹8.08 Cr | 1.86% |
Laxmi Dental Ltd | Equity | ₹8.06 Cr | 1.85% |
Hikal Ltd | Equity | ₹7.82 Cr | 1.80% |
Krsnaa Diagnostics Ltd | Equity | ₹6.4 Cr | 1.47% |
Gland Pharma Ltd | Equity | ₹6.35 Cr | 1.46% |
Orchid Pharma Ltd | Equity | ₹6.29 Cr | 1.45% |
Net Current Assets/(Liabilities) | Cash | ₹-3.87 Cr | 0.89% |
Large Cap Stocks
35.00%
Mid Cap Stocks
28.20%
Small Cap Stocks
29.83%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹401.73 Cr | 92.45% |
Basic Materials | ₹10.59 Cr | 2.44% |
Standard Deviation
This fund
--
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since December 2023
Since December 2023
Since March 2024
ISIN | INF174KA1PW4 | Expense Ratio | 2.40% | Exit Load | No Charges | Fund Size | ₹435 Cr | Age | 1 year 6 months | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹321.02 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹321.02 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹108.88 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹108.88 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹331.66 Cr | 24.2% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹331.66 Cr | 26.4% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹10.25 Cr | 12.4% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹434.55 Cr | 13.7% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹434.55 Cr | 11.8% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹1704.87 Cr | 24.6% |
Total AUM
₹5,29,477 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Your principal amount will be at Very High Risk